GSK US

We are uniting science, technology and talent to get ahead of disease together.

Our community guidelines:

[GSK US @GSKUS]

#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: https://t.co/BhBJ8aEkmL

[GSK @GSK]

#News for #investors and #media:

We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.

Find out more: https://t.co/r7yUaG73LP

[GSK US @GSKUS]

#News for #investors and #media:
We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: https://t.co/cq4r2CkLYB.

[GSK US @GSKUS]

Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management.

At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.

[GSK @GSK]

News for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSK

[GSK @GSK]

News for #Investors and #Media

Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026.

Find out more: https://t.co/pcb6qYzkHJ

$GSK #Q1Results

[GSK US @GSKUS]

@4xuHkAOxS29TACZ Hi Hussein, thanks for reaching out. We'd love to help but industry regulations mean we're not able to discuss our medicines with you. Your doctor or healthcare professional will be best placed to support. We hope this helps.

[GSK US @GSKUS]

News for #Investors and #Media: Today, we announced the US Food and Drug Administration accepted our application for a potential first-in-class treatment for chronic hepatitis B. Learn more: https://t.co/NKYLlYNMcr

[GSK US @GSKUS]

Hello Anil. Thank you for reaching out to us, we understand your frustrations. Please contact our US Response Center at 888-825-5249. They are available Monday - Friday, from 8:00am to 5:30pm (EST). We hope this helps and encourage you to reach out to them for further assistance. Thank you.

[GSK US @GSKUS]

Current treatments for #cUTIs caused by drug-resistant organisms often require hospitalization. The lack of oral treatments can result in extended hospital stays, ultimately having a negative impact on patients’ quality of life.

We remain focused to address the growing issue of antimicrobial resistance.

#ESCMIDGlobal2026

[GSK US @GSKUS]

#News for #Investors and #Media: At #SGO2026, we presented new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: https://t.co/s6OODdIBk2.

[GSK US @GSKUS]

@anilguptamd Hello Anil, thanks for your message. Your local GSK team will be best placed to support with your enquiry. Find out how to get in touch: https://t.co/r8m0DFwAEe. We hope this helps.

[GSK US @GSKUS]

Our partnership with the lupus community has always been fueled by a clear purpose: to improve the outcomes for people living with lupus.

This dedication to advancing breakthroughs continues to drive our work as we look ahead to the future of lupus care.

#Lupus #AheadTogether

[GSK US @GSKUS]

Hi, thanks for your message. We've received several reports about a recruitment scam circulating from [email protected] for a Data Analyst role. We're actively investigating this, and we appreciate you bringing it to our attention. If you've received one of these emails, please help us by forwarding all relevant details and materials to [email protected]. A reminder that GSK will never ask for payment at any stage of our recruitment process. Thank you for your support.

[GSK US @GSKUS]

We‘ve topped the Access to Medicine Index's 2026 Antimicrobial Resistance Benchmark, reflecting our continuous focus on delivering innovative antibiotic medicines and vaccines for patients with significant unmet medical need.

Check out our #AMR podcast: https://t.co/IR1RZeN4cT

[GSK @GSK]

Our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.

Take a look at the highlights ⤵️

🔗 Investors and media can read more: https://t.co/2OYBDgdcMOur latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.

Take a look at the highlights ⤵️

🔗 Investors and media can read more: https://t.co/2OYBDgdcMOur latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.

Take a look at the highlights ⤵️

🔗 Investors and media can read more: https://t.co/2OYBDgdcMOur latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.

Take a look at the highlights ⤵️

🔗 Investors and media can read more: https://t.co/2OYBDgdcMOur latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.

Take a look at the highlights ⤵️

🔗 Investors and media can read more: https://t.co/2OYBDgdcM6

[GSK US @GSKUS]

We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more. If you can’t attend, you can learn more about our work here: https://t.co/164aJaWugN 🫁

[GSK US @GSKUS]

@hasebetomoya1 Hello. Flonase is now made by Haleon, not GSK. We encourage you to reach out with further feedback or questions via their channel @Haleon_health or their website, https://t.co/0Ska5TYTpp. Sorry we couldn't be of help this time.

[GSK @GSK]

Explore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSExplore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSExplore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSExplore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSExplore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSExplore the key highlights from our Q4 and full year 2025 results announcement ⤵️

More information for media and investors: https://t.co/LNG81hA3xg $GSK